Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:1225 (26 November), doi:10.1136/bmj.331.7527.1225-a
Rebecca Coombes
London
| The first 150 words of the full text of this article appear below. |
The pharmaceutical industry published a tougher code of conduct this week after criticism that self regulation was failing to stop the circulation of misleading claims about products. The revised code from the Association of the British Pharmaceutical Industry follows a critical health select committee report in April (
BMJ
2005;330: 805
As evidence that self regulation wasn't working well, the report cited examples of breaches of advertising regulations; cover-ups of negative medical information; and giving misleading information to prescribers. MPs also criticised the long delays taken by the industry to investigate complaints.
As with previous codes, the new code of conduct, to be launched in January, is a voluntary code, without the backing of the law. It covers communication with the public and the promotion of prescription only medicines to health professionals. The main changes include a tightening of rules governing hospitality so that delegates sponsored
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?